Restricted Research - Award List, Note/Discussion Page
Fiscal Year: 2023
1541 The University of Texas at Arlington (143429)
Principal Investigator: Hanli Liu,hanli@uta.edu,(817) 272-2054
Total Amount of Contract, Award, or Gift (Annual before 2011): $ 388,494
Exceeds $250,000 (Is it flagged?): Yes
Start and End Dates: 9/15/22 - 8/31/24
Restricted Research: YES
Academic Discipline: Department of Bioengineering
Department, Center, School, or Institute: none
Title of Contract, Award, or Gift: Digital biomarkers for Alzheimer's Disease with compact dual-mode brain sensing
Name of Granting or Contracting Agency/Entity:
National Institutes of Health (NIH)
CFDA Link: HHS
93.866
Program Title:
NIH R21
CFDA Linked: Aging Research
Note:
(SAM Category 1.1.1.) It is known that the ADRD brain has significant degenerations in all anatomical, biological, and pathological aspects. Such deteriorations must be accompanied by cerebral dysfunctions of metabolic, hemodynamic, and electrophysiological (MHE) activities in the ADRD brain. Also, the progression from early to late stage of ADRD takes years and often shows no or few symptoms at the early stage. However, cutting-edge, biological-construct-based, brain-sensing technology may enable to detect progressive degeneration of MHE-activity. The hypothesis of this study is that patients with ADRD are impaired in their cerebral MHE functions and can be sensed digitally by compact, dual-mode broadband near infrared spectroscopy (bbNIRS) and electroencephalogram (EEG). Specifically, we wish to conduct a proof-of-principle study, namely, to develop, test, and demonstrate a novel ADRD-sensing system by integrating bbNIRS and EEG (i.e., bbNIRS-EEG) as a compact, low-cost, non-invasive, and dual-mode device. The proposed bbNIRS-EEG device enables to perform resting-state human brain measurements which quantify (1) cerebral metabolism, (2) cerebral blood volume and oxygenation, and (3) brain rhythms oscillating at different frequencies, respectively, from both normal and AD subjects. For this R21 proposal, specifically, we have two aims: Aim 1 is to establish digital measures of cerebral MHE-activities of healthy human brains by implementing a compact bbNIRS-EEG system. Aim 2 is to identify appropriate biomarkers that can be used to separate healthy older adults from patients with ADRD as well as to stratify ADRD patients with mild and moderate-to-server dementia. The outcome of this R21 will provide proof of principle that dual-mode bbNIRS-EEG enables to identify critical biomarkers that can be used for detection of ADRD at mild or moderate-to-severe stage, permitting us to pursue a larger research project (i.e., R01) for promoting digital biomarkers for ADRD by dual-modal bbNIRS-EEG.
Discussion: No discussion notes